2021年后，非达索霉素成功帮助艰难梭菌感染的成年患者出院:经济障碍最终会消失吗?

Clinical Infectious Diseases: An Official Publication of the Infectious Diseases Society of America Pub Date : 2022-08-31 DOI:10.1093/cid/ciab1061

Noah Fang, David Ha, Kimberly Dong, Thomas Leung, Sydney Lee, Marisa Holubar, Lina Meng

{"title":"2021年后，非达索霉素成功帮助艰难梭菌感染的成年患者出院:经济障碍最终会消失吗?","authors":"Noah Fang, David Ha, Kimberly Dong, Thomas Leung, Sydney Lee, Marisa Holubar, Lina Meng","doi":"10.1093/cid/ciab1061","DOIUrl":null,"url":null,"abstract":"We reviewed Clostridioides difficile-positive patients discharged on fidaxomicin after local adoption of 2021 C. difficile infection (CDI) guidelines. From 14 June to 3 October 2021, 80% (12/15) had copayments of $0-$35 and 27% (4/15) required prior authorization. The 30-day CDI recurrence was 7%.","PeriodicalId":10421,"journal":{"name":"Clinical Infectious Diseases: An Official Publication of the Infectious Diseases Society of America","volume":" ","pages":"519-521"},"PeriodicalIF":0.0000,"publicationDate":"2022-08-31","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":"{\"title\":\"Successful Fidaxomicin Hospital Discharges of Adult Patients With Clostridioides difficile Infections Post-2021 Guidelines: Are Economic Barriers Finally Coming Down?\",\"authors\":\"Noah Fang, David Ha, Kimberly Dong, Thomas Leung, Sydney Lee, Marisa Holubar, Lina Meng\",\"doi\":\"10.1093/cid/ciab1061\",\"DOIUrl\":null,\"url\":null,\"abstract\":\"We reviewed Clostridioides difficile-positive patients discharged on fidaxomicin after local adoption of 2021 C. difficile infection (CDI) guidelines. From 14 June to 3 October 2021, 80% (12/15) had copayments of $0-$35 and 27% (4/15) required prior authorization. The 30-day CDI recurrence was 7%.\",\"PeriodicalId\":10421,\"journal\":{\"name\":\"Clinical Infectious Diseases: An Official Publication of the Infectious Diseases Society of America\",\"volume\":\" \",\"pages\":\"519-521\"},\"PeriodicalIF\":0.0000,\"publicationDate\":\"2022-08-31\",\"publicationTypes\":\"Journal Article\",\"fieldsOfStudy\":null,\"isOpenAccess\":false,\"openAccessPdf\":\"\",\"citationCount\":\"0\",\"resultStr\":null,\"platform\":\"Semanticscholar\",\"paperid\":null,\"PeriodicalName\":\"Clinical Infectious Diseases: An Official Publication of the Infectious Diseases Society of America\",\"FirstCategoryId\":\"3\",\"ListUrlMain\":\"https://doi.org/10.1093/cid/ciab1061\",\"RegionNum\":0,\"RegionCategory\":null,\"ArticlePicture\":[],\"TitleCN\":null,\"AbstractTextCN\":null,\"PMCID\":null,\"EPubDate\":\"\",\"PubModel\":\"\",\"JCR\":\"\",\"JCRName\":\"\",\"Score\":null,\"Total\":0}","platform":"Semanticscholar","paperid":null,"PeriodicalName":"Clinical Infectious Diseases: An Official Publication of the Infectious Diseases Society of America","FirstCategoryId":"3","ListUrlMain":"https://doi.org/10.1093/cid/ciab1061","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"","JCRName":"","Score":null,"Total":0}

引用次数: 0

摘要

我们回顾了当地采用2021年艰难梭菌感染(CDI)指南后使用非达霉素出院的艰难梭菌阳性患者。从2021年6月14日到10月3日，80%(12/15)的共付额为0- 35美元，27%(4/15)的共付额需要事先授权。30天CDI复发率为7%。

本文章由计算机程序翻译，如有差异，请以英文原文为准。

查看原文本刊更多论文

Successful Fidaxomicin Hospital Discharges of Adult Patients With Clostridioides difficile Infections Post-2021 Guidelines: Are Economic Barriers Finally Coming Down?

We reviewed Clostridioides difficile-positive patients discharged on fidaxomicin after local adoption of 2021 C. difficile infection (CDI) guidelines. From 14 June to 3 October 2021, 80% (12/15) had copayments of $0-$35 and 27% (4/15) required prior authorization. The 30-day CDI recurrence was 7%.

求助全文

通过发布文献求助，成功后即可免费获取论文全文。去求助

来源期刊

Clinical Infectious Diseases: An Official Publication of the Infectious Diseases Society of America

自引率

0.00%

发文量